CD55 Monoclonal Antibody

$Lane 1: Hela cell lysates probed with CD55 Monoclonal Antibody, Unconjugated (bsm-51537M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Hela cell lysates probed with CD55 Monoclonal Antibody, Unconjugated (bsm-51537M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

Reactivity

Human

Overview
Catalog #	bsm-51537m
Product Name	CD55 Monoclonal Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	KLH conjugated synthetic peptide derived from human CD55
Clonality	Monoclonal
Clone #	D5FF2
Isotype	IgG1
Concentration	0.5ug/ul
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	1604
Swiss Prot	P08174
Subcellular location	Cell membrane
Synonyms	CD 55; CD55 antigen; CD55 Cromer blood group system; CD55 molecule; CD55 molecule, decay accelerating factor for complement (Cromer blood group); Cd55a; Complement decay accelerating factor; Complement decay-accelerating factor; Complement decay-accelerating factor, GPI-anchored; CR; CROM; Cromer Blood Group antigen; Cromer blood group system; DAF; Daf-GPI; DAF_HUMAN; Daf1; Dcay accelerating factor for complement (CD55, Cromer blood group system); Decay accelarating factor 1, isoform CRA_a; Decay accelerating factor (GPI-form); Decay Accelerating Factor for Complement; Decay accelerating factor GPI-form; Decay accelerating factor soluble-form; GPI-DAF; TC.
Background	This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.
Application Dilution
WB	=1:500-2000